Neuroblastomas With Sensitivity To BET Bromodomain Inhibitors May Be Identified By Biomarker

Neuroblastoma, the most common malignant tumor of early childhood, is frequently associated with the presence of MYCN amplification, a genetic biomarker associated with poor prognosis. Researchers have determined that tumors containing MYCN amplification are sensitive to a new class of drugs, BET bromodomain inhibitors. The researchers made this discovery in a preclinical study, which was funded in part by a Stand Up To Cancer Innovative Research Grant and was published in Cancer Discovery, a journal of the American Association for Cancer Research...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Neurology / Neuroscience Source Type: news